Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2004-03-30
2009-12-22
McGarry, Sean (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023400, C435S006120, C435S069100, C435S091100, C435S325000
Reexamination Certificate
active
07635763
ABSTRACT:
Methods and compositions are provided that allow for high-level expression of a factor VIII polypeptide. More specifically, methods and compositions are provided comprising nucleic acid and amino acid sequences comprising a modified factor VIII that result in high-level expression of the polypeptide. The methods and compositions of the invention find use in the treatment of factor VIII deficiency including, for example, hemophilia A.
REFERENCES:
patent: 5364771 (1994-11-01), Lollar et al.
patent: 5583209 (1996-12-01), Lollar et al.
patent: 5663060 (1997-09-01), Lollar et al.
patent: 5744446 (1998-04-01), Lollar et al.
patent: 5859204 (1999-01-01), Lollar
patent: 5888974 (1999-03-01), Lollar et al.
patent: 5935935 (1999-08-01), Connelly et al.
patent: 6180371 (2001-01-01), Lollar
patent: 6200560 (2001-03-01), Couto et al.
patent: 6376463 (2002-04-01), Lollar
patent: 6458563 (2002-10-01), Lollar
patent: 6642028 (2003-11-01), Ill et al.
patent: 6818439 (2004-11-01), Jolly et al.
patent: WO 00/71141 (2000-11-01), None
patent: WO 01/68109 (2001-09-01), None
Hemostasis, Thrombosis, and Vascular Biology; “Reduction of the Antigenicity of Factor VIII Toward Complex Inhibitory Antibody Plasmas Using Multiply-Substituted Hybrid Human/Porcine Factor VIII Molecules”; Rachel T. Barrow, John F. Healey, David Gailani, Dorothea Scandella, and Pete Lollar; 2000 by The American Society of Hematology; Blood, Jan. 15, 2000—vol. 95, No. 2.
The Journal of Biological Chemistry; “High Level Expression of Recombinant Porcine Coagulation Factor VIII”; Christopher B. Doering, John F. Healey, Ernest T. Parker, Rachel T. Barrow, and Pete Lollar; From the Winship Cancer Institute, Emory University, Atlanta , Georgia; 2002 By The American Society for Biochemistry and Molecular Biology, Inc.; vol. 277, No. 41, Issue of Oct. 11, pp. 38345-38349, 2002.
Barrow, R.T., et al., “Antigenicity of Putative Phospholipid Membrane-Binding Residues in Factor VIII,”Blood, 2001, pp. 169-174, vol. 97 No. 1.
Barrow, R.T., et al., “Reduction of the Antigenicity of Factor VIII Toward Complex Inhibitory Antibody Plasmas Using Multiply-Substituted Hybrid Human/Porcine Factor VIII Molecules,”Blood, 2000, pp. 564-568, vol. 95, No. 2.
Bowie, E.J., and C.A. Owen, “The Clinical and Laboratory Diagnosis of Hemorrhagic Disorders,”Grune&Stratton, Inc., Orlando, 1984, pp. 43-72.
Chang, J., et al., “Changing Residue 338 in Human Factor IX from Arginine to Alanine Causes an Increase in Catalytic Activity,”The Journal of Biological Chemistry, 1998, pp. 12089-12094, vol. 273, No. 20, The American Society for Biochemistry and Molecular Biology, Inc., USA.
Doering, C.B., et al., “High Level Expression of Recombinant Porcine Coagulation Factor VIII,”The Journal of Biological Chemistry, 2002, pp. 38345-38349, vol. 277, No. 41, The American Society for Biochemistry and Molecular Biology, Inc., USA.
Funk, W.D., et al., “Expression of the Amino-Terminal Half-Molecule of Human Serum Transferrin in Cultured Cells and Characterization of Recombinant Protein,”Biochemistry, 1990, pp. 1654-1660, vol. 29, No. 6.
Healey, J.F., et al., “Residues Glu2181-Val2243 Contain a Major Determinant of the Inhibitory Epitope in the C2 Domain of Human Factor VIII,”Blood, 1998, pp. 3701-3709, vol. 92, No. 10.
Healey, J.F., et al., “Residues 484-508 Contain a Major Determinant of the Inhibitory Epitope in the A2 Domain of Human Factor VIII,”The Journal of Biological Chemistry, 1995, pp. 14505-14509, vol. 270, No. 24.
Kaufman, R.J., et al., “Biosynthesis, Assembly and Secretion of Coagulation Factor VIII,”Blood Coagulation and Fibrinolysis, 1997, pp. S3-S14, vol. 8 (Suppl 2), Rapid science Publishers.
Lind, P., et al., “Novel Forms of B-Domain-Deleted Recombinant Factor VIII Molecules Construction and Biochemical Characterization,”Eur. J. Biochem., 1995, pp. 19-27, vol. 232.
Lollar, P., “Mapping factor VIII Inhibitor Epitopes Using Hybrid Human/Porcine Factor VIII Molecules,”Haematologica, 2000, pp. 26-30, vol. 85 (Suppl. to n. 10).
Lubin, I.M., et al., “Elimination of a Major Inhibitor Epitope in Factor VIII,”The Journal of Biological Chemistry, 1994, pp 8639-8641, vol. 269, No. 12, The American Society for Biochemistry and Molecular Biology, Inc., USA.
Prescott, R., et al., “The Inhibitor Antibody Response is More Complex in Hemophilia A Patients Than in Most Nonhemophiliacs with Factor VIII Autoantibodies,”Blood, 1997, pp. 3663-3671, vol. 89, No. 10.
Vehar, G.A., et al., “Structure of Human Factor VIII,”Nature, 1984, pp. 337-342, vol. 312.
Zhong, D., et al., “Some Human Inhibitor Antibodies Interfere with Factor VIII Binding to Factor IX,” 1998, pp. 136-142, vol. 92, No. 1.
Brinks Hofer Gilson & Lione
Expression Therapeutics, LLC.
Gibbs Terra Cotta
McGarry Sean
Schafer Heather N.
LandOfFree
Nucleic acid and amino acid sequences encoding high-level... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acid and amino acid sequences encoding high-level..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acid and amino acid sequences encoding high-level... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4067667